• Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World
Newsy Today
news of today
Home - Genomic
Tag:

Genomic

Health

Australia’s Diphtheria Outbreak: Lessons on Vaccines and Housing

by Chief Editor June 15, 2026
written by Chief Editor

A recent diphtheria outbreak in Australia’s Northern Territory resulted in 131 confirmed cases between January 2025 and April 2026, marking the region’s first significant local recurrence in two decades. According to a study published in Eurosurveillance, the outbreak was driven by the sequence type 381 strain, primarily affecting Aboriginal communities. While high childhood vaccination rates prevented widespread mortality, the emergence of both cutaneous and respiratory cases highlights critical gaps in booster coverage and the influence of overcrowded living conditions on disease transmission.

Why is diphtheria re-emerging in highly vaccinated populations?

Diphtheria persists because environmental and social factors can override the protection provided by childhood immunization. Researchers found that while 95% of the 131 cases occurred in Aboriginal Australians, the disease thrived in settings characterized by socioeconomic disadvantage and crowded housing. According to the Eurosurveillance report, even in populations with high primary vaccination coverage, a lack of booster doses—particularly those not updated within the last 10 years—leaves adults vulnerable to infection. The study noted that the sole fatality during the outbreak was an adult who had completed their childhood series but had missed a booster shot for over a decade.

Why is diphtheria re-emerging in highly vaccinated populations?
Did you know?
Diphtheria does not always present as a severe respiratory illness. In the 2025-2026 Northern Territory outbreak, 97 of the 131 cases were cutaneous, meaning they manifested as skin lesions rather than the classic throat-based pseudomembrane historically associated with the disease.

How does the 2025-2026 outbreak compare to previous data?

This outbreak represents a distinct epidemiological shift compared to historical norms. Genomic analysis conducted by Territory Pathology revealed that the dominant strain, sequence type 381, is genetically distinct from strains identified in Queensland during earlier outbreaks. While Queensland strains were linked to previous regional clusters, the Northern Territory isolates showed a median genetic difference of only three single-nucleotide polymorphisms (SNPs), suggesting a rapid, localized transmission cycle. Time-scaled phylogenetic analysis traced the common ancestor of this specific outbreak strain back to approximately 2017, indicating that the bacteria had been circulating or evolving in the region for years before the 2025 surge.

How does the 2025-2026 outbreak compare to previous data?

What are the primary clinical challenges for healthcare providers?

Modern diphtheria outbreaks are increasingly difficult to recognize because they often deviate from textbook descriptions. According to the study, only a small minority of patients developed the classic pseudomembrane, which has historically been the primary diagnostic indicator for clinicians. Instead, patients presented with a range of symptoms including pharyngitis, tonsillitis, and fever. Furthermore, cutaneous cases were frequently polymicrobial, with Corynebacterium diphtheriae co-isolated alongside Staphylococcus aureus and Group A streptococcus. This complexity makes it essential for health departments to utilize genomic surveillance and rapid laboratory identification, such as mass spectrometry and qPCR, to confirm toxin production.

NT Health confirms only one possible diphtheria-related death amid outbreak | ABC NEWS

Pro Tips for Public Health Surveillance

  • Prioritize Boosters: Focus outreach on adults who have not received a diphtheria-containing vaccine in the last decade.
  • Screen Skin Lesions: In regions with known outbreaks, clinicians should culture skin lesions for C. diphtheriae, not just throat swabs.
  • Standardize Treatment: Current findings confirm that the circulating ST381 strain remains susceptible to standard antibiotics like penicillin and erythromycin, allowing for effective treatment if identified early.

Frequently Asked Questions

Is the diphtheria vaccine still effective?
Yes. High vaccination rates kept the majority of the 131 cases relatively mild. However, the study confirms that immunity wanes over time, making booster doses necessary for long-term protection.

How is diphtheria transmitted?
The disease spreads through respiratory droplets or direct contact with wound exudate. Overcrowded living conditions significantly increase the risk of transmission.

What are the long-term solutions for preventing future outbreaks?
Researchers recommend a multi-faceted approach: sustained improvements to housing, better access to primary healthcare, aggressive contact tracing, and stronger collaboration with Aboriginal Community Controlled Health Organizations.

Have you checked your vaccination records recently? Consult your local healthcare provider to ensure your diphtheria booster is up to date. Subscribe to our newsletter for more updates on infectious disease research and public health trends.

June 15, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

AI Model Predicts Cancer Treatment Response from Genetic Mutations

by Chief Editor May 26, 2026
written by Chief Editor

Beyond Biomarkers: The AI Revolution in Precision Oncology

Genetic sequencing has become a standard tool in modern cancer care, yet clinicians often face a significant hurdle: interpreting the complex landscape of mutations within a tumor. While genetic testing is fast and cost-effective, current treatment strategies rely on a limited number of validated biomarkers. In fact, only about 8% of cancer cases are successfully matched to an FDA-approved therapy based on existing genetic protocols.

Beyond Biomarkers: The AI Revolution in Precision Oncology
Model Predicts Cancer Treatment Response University of California

A breakthrough from researchers at the University of California San Diego, detailed in the journal Cancer Discovery, aims to bridge this gap. By developing a new artificial intelligence model called MutationProjector, scientists are moving toward a more functional, comprehensive understanding of cancer genomics.

How MutationProjector Decodes Tumor Complexity

Unlike traditional methods that hunt for specific, well-known biomarkers, MutationProjector functions as a general-purpose foundation model. It was trained on genomic data from more than 30,000 tumors across 10 distinct solid cancer types.

How MutationProjector Decodes Tumor Complexity
MutationProjector cancer model research

The model analyzes the broader combination of genetic alterations rather than individual mutations. By doing so, it creates a compact representation of a tumor’s biological state, allowing researchers to pinpoint which molecular pathways are disrupted. As Trey Ideker, PhD, professor of medicine at UC San Diego School of Medicine and director of the Big Data Institute at the University of Oxford, noted, “Genetic sequencing is already routine in cancer care, but we still struggle to fully interpret the many mutations found in a patient’s tumor.”

Did you know?

Many cancer mutations are individually rare, making them nearly impossible to study in isolation. AI foundation models allow scientists to integrate molecular network knowledge to detect patterns that conventional methods would otherwise miss.

Improving Patient Outcomes Through Predictive Intelligence

Testing across independent patient cohorts—including those with lung cancer, bladder cancer, and melanoma—revealed that MutationProjector matched or surpassed existing methods for predicting responses to both chemotherapy and immunotherapy. The model’s ability to identify both known and unexpected biomarkers offers a promising path for refining patient stratification.

Trey Ideker – Building The Mind of Cancer

“Our goal with MutationProjector was to build a general-purpose model that can learn from tens of thousands of tumor genomes and turn those mutation patterns into more precise predictions about treatment response,” said Ideker.

The Future of Precision Oncology

The researchers emphasize that the model is designed to be interpretable. In clinical settings, understanding why an AI makes a prediction is as vital as the prediction itself. This transparency helps clinicians relate tumor genotypes directly to treatment decisions.

The Future of Precision Oncology
Trey Ideker UC San Diego

Looking ahead, the team intends to expand the model’s capabilities by incorporating diverse data sources, including:

  • Medical imaging
  • Transcriptomics
  • Electronic health records
  • International cancer genome datasets
Pro Tip:

Stay updated on the latest breakthroughs in AI-driven medicine by subscribing to our oncology research newsletter. We track the latest developments in precision medicine as they move from the lab to the clinic.

Frequently Asked Questions

What is a foundation model in cancer research?
A foundation model is a large-scale AI trained on vast amounts of data—in this case, over 30,000 tumor genomes—that can be adapted to perform various tasks, such as predicting how a specific tumor will respond to treatment.
Why is it difficult to match patients to therapy using genetics?
Currently, treatment stratification relies on a small number of known biomarkers. Because many mutations are rare and complex, standard testing often fails to find a match for a significant majority of patients.
Can this model be used for all types of cancer?
The current study focused on 10 solid cancer types, but the researchers are actively working to expand the model’s scope to include additional cancer types and more diverse clinical data sources.

For more in-depth insights into the future of healthcare technology, explore our Precision Medicine Archive. Have questions about how AI is changing your field? Let us know in the comments below!

May 26, 2026 0 comments
0 FacebookTwitterPinterestEmail
Tech

AI Uncovers Hidden Antibiotic Resistance Genes

by Chief Editor May 25, 2026
written by Chief Editor

The AI Arms Race: How Genomic Language Models are Outsmarting Superbugs

The battle against antimicrobial resistance (AMR) has always been a high-stakes game of evolutionary chess. For decades, scientists have relied on a specific set of rules to identify the “weapons” bacteria use to survive our drugs: antibiotic resistance genes (ARGs). But as bacteria evolve at breakneck speeds, our traditional methods of detection are beginning to show their age.

A groundbreaking study recently published in npj Antimicrobials and Resistance suggests that the next generation of defense won’t come from better databases, but from better “understanding.” The introduction of resLens—a family of genomic language models (gLMs)—is signaling a paradigm shift in how we track the invisible evolution of superbugs.

The Flaw in Our Current Defense: The Database Bottleneck

Historically, detecting antibiotic resistance has relied heavily on alignment-based tools. Think of this like a “most wanted” poster system. If a bacterium carries a gene that looks almost identical to one in our existing database, we catch it. Common methods include k-mer approaches, best-hit algorithms, and Hidden Markov Models (HMM).

However, this “matching” strategy has a fatal flaw: it only works if the bacteria play by the rules we’ve already documented. If a gene evolves a new sequence or a different mechanism to resist a drug, it becomes “invisible” to these tools. As the global resistome expands, our databases simply cannot keep up with the sheer scale and pace of microbial evolution.

Did you know?
The “resistome” refers to the collection of all antibiotic resistance genes within a specific environment or organism. It is constantly shifting as bacteria exchange genetic material through horizontal gene transfer.

resLens: Teaching AI to “Speak” DNA

Rather than just looking for a match, the researchers behind resLens decided to teach AI to understand the “language” of DNA. Unlike previous deep learning models that had to learn everything from scratch, resLens utilizes transfer learning. It takes a pre-trained DNA language model—one that already understands the fundamental grammar of genetic sequences—and fine-tunes it specifically to recognize resistance patterns.

Why Transfer Learning Changes Everything

This approach allows the model to identify resistance even when the sequence is significantly different from anything currently stored in a database. In the study, researchers tested the model against “withheld” gene families—genes the model had never seen before.

The results were telling. When tested against the blaADC gene family (which confers resistance to beta-lactams), traditional tools like ResFinder failed to identify a single instance. In contrast, the resLens models were able to accurately classify these novel threats. This ability to generalize beyond known sequences is the “holy grail” of bioinformatics.

“The rise of antibiotic resistance necessitates advanced tools to detect and analyze ARGs… ResLens leverages latent genomic representations to enhance detection and analysis.” — Summary of research findings from the study.

Future Frontiers: Where AMR Detection is Heading

The success of resLens is more than just a technical milestone; it is a roadmap for the future of infectious disease management. As we look toward the next decade, several key trends are emerging.

Future Frontiers: Where AMR Detection is Heading
Oxford Nanopore

1. Real-Time Evolutionary Surveillance

We are moving toward a future of “active surveillance.” Instead of reacting to a hospital outbreak, genomic language models could be integrated into environmental monitoring systems—testing sewage or hospital surfaces in real-time to spot emerging resistance patterns before they reach the patient population.

2. The Rise of Long-Read Diagnostics

The study highlighted that resLens performs exceptionally well on long-read (LR) sequencing data. As technologies like Oxford Nanopore and PacBio become more portable and affordable, we could see “point-of-care” genomic sequencing. Imagine a clinician sequencing a patient’s sample and receiving an AI-driven resistance profile in minutes, rather than days.

3. From Screening to Precision Medicine

While the researchers caution that resLens is currently a screening and hypothesis-generation tool rather than a final clinical diagnostic, the trajectory is clear. Eventually, these models will assist in “precision prescribing”—matching a specific patient’s infection with the exact antibiotic most likely to work, based on the unique genomic signature of their pathogen.

We don't know what most microbial genes do. Will genomic language models help? (Yunha Hwang, Ep #7)
Pro Tip for Researchers:
When utilizing genomic language models for AMR, always validate AI-predicted resistance with phenotypic testing. While gLMs are superior at spotting novel genes, they can still produce false positives in highly complex genomic environments.

Frequently Asked Questions

How is a genomic language model different from a standard search tool?

A standard search tool (like BLAST) looks for exact or near-exact matches in a database. A genomic language model (gLM) learns the underlying patterns and “syntax” of DNA, allowing it to recognize a gene’s function even if its sequence has changed significantly.

Can resLens replace traditional antibiotic testing?

Not yet. The study emphasizes that while resLens is incredibly powerful for screening and finding novel genes, it should be used to generate hypotheses that are then confirmed through laboratory-based phenotypic testing.

What are the limitations of current AI models in microbiology?

The main limitation is “distribution shift.” If a model is trained on a specific set of data, its accuracy can drop when it encounters highly unusual or vastly different genetic sequences. Continuous training on diverse datasets is essential.


What do you think? Will AI-driven genomics be the key to winning the war against superbugs, or are we still one step behind microbial evolution? Leave a comment below and join the discussion!

To stay updated on the latest breakthroughs in bioinformatics and AI-driven healthcare, subscribe to our newsletter or explore our latest articles on genomic technology.

May 25, 2026 0 comments
0 FacebookTwitterPinterestEmail
Tech

Tracking the aging process across tens of millions of individual cells

by Chief Editor May 13, 2026
written by Chief Editor

The Shift Toward “Optics-Free” Biology: Mapping the Aging Brain

For centuries, the microscope has been the gold standard for understanding tissue organization. However, a paradigm shift is occurring in how we “see” the biological drivers of aging. The traditional reliance on imaging is being supplemented—and in some cases replaced—by high-throughput single-cell genomic analysis.

View this post on Instagram about Mapping the Aging Brain, Laboratory of Single
From Instagram — related to Mapping the Aging Brain, Laboratory of Single

A significant breakthrough in this field comes from the Laboratory of Single-Cell Genomics and Population Dynamics at Rockefeller University. Led by Assistant Professor Junyue Cao, the team has introduced tools that allow researchers to examine the molecular state of tens of millions of cells simultaneously, bypassing the need for traditional microscopy to understand tissue layout.

Did you know? DNA can act as a “molecular ruler.” New techniques use DNA-based signals to record which molecules are close to one another, allowing scientists to reconstruct the physical layout of a tissue using sequencing data alone.

Why Spatial Context is the New Frontier

Studying cells in isolation is often compared to reading individual words from a book after the pages have been torn apart. To truly understand aging, researchers need the context of “cellular neighborhoods”—knowing not just what a cell is, but who its neighbors are and where it is located.

Here’s where IRISeq comes into play. As described in Nature Neuroscience, this optics-free approach uses millions of barcoded, micrometer-sized beads to capture local gene expression. By exchanging DNA-based signals, these beads allow researchers to rebuild tissue layouts at varying levels of detail.

The implications for aging research are profound. Using IRISeq, researchers have identified inflammatory cellular neighborhoods in the aging brain, specifically noting that inflammatory subtypes of astrocytes, oligodendrocytes, and microglia tend to cluster together in white matter. This suggests that white matter may be a highly vulnerable region where disease-associated states reinforce one another.

Precision Targeting of Rare Cellular Drivers

One of the greatest challenges in genomics is the “needle in a haystack” problem. In a mixed population of cells, the most biologically relevant cells—those driving a disease or the aging process—are often the rarest.

To solve this, Cao’s lab developed EnrichSci, a method detailed in Cell Genomics. Unlike standard sequencing, EnrichSci first isolates and enriches rare target cell populations before zooming in on their molecular programming. This increases the percentage of target cells in a sample, allowing for much deeper analysis.

The Hidden Role of Exons in Neurodegeneration

By applying EnrichSci to the aging mouse brain, researchers focused on subtypes of oligodendrocytes—cells that ensheath neuronal axons in the brain and spinal cord. These cells are closely linked to neurodegenerative diseases.

The research uncovered that aging isn’t just about gene expression; it’s also about exons. As Andrew Liao, an M.D.-Ph.D. Student in the lab, explains, exons are the parts of genes that form mature RNA transcripts. The discovery of significant changes in these elements suggests that post-transcriptional regulation plays a critical role in how the brain ages.

Pro Tip for Researchers: When analyzing age-related decline, look beyond simple gene “on/off” switches. Investigating alternative splicing and exon changes can reveal regulatory shifts that traditional RNA sequencing might miss.

Future Trends: Beyond Aging and Into Clinical Diagnostics

While the current focus is on the aging process, the trajectory of these technologies points toward a broader application in personalized medicine and oncology.

  • Oncology: IRISeq could be scaled to study how immune cells interact during cancer progression, identifying the exact “neighborhoods” where tumors evade the immune system.
  • Pharmacological Interventions: These tools allow for the study of drug responses at a scale previously considered unfeasible, observing how a treatment changes the molecular state of millions of cells across a tissue.
  • Localized Inflammation: The discovery that lymphocytes drive inflammation specifically near the brain’s ventricles (fluid-filled spaces) highlights the potential for localized, rather than systemic, anti-aging interventions.

As we move toward a future of precision medicine, the ability to map these interactions without the cost and limitations of traditional imaging will likely accelerate the discovery of new biomarkers for dementia and other age-related conditions.

Frequently Asked Questions

How does IRISeq differ from traditional microscopy?

Unlike microscopes, which take physical pictures of tissues, IRISeq uses DNA barcodes and beads to capture gene expression and spatial signals. This allows researchers to “see” the tissue layout through sequencing data, which is often more cost-effective and scalable for large sample sets.

What are oligodendrocytes and why do they matter in aging?

Oligodendrocytes are cells found in the central nervous system that protect neuronal axons. Because they are linked to neurodegenerative diseases, studying their molecular shifts during aging helps researchers identify potential targets for therapeutic intervention.

What is the significance of “post-transcriptional regulation”?

It refers to the changes that happen to RNA after it has been transcribed from DNA but before it is translated into a protein. Changes in exons, for example, can alter the final protein product, adding another layer of complexity to how cells age.

Want to stay updated on the latest breakthroughs in genomic medicine and longevity? Subscribe to our newsletter or leave a comment below to share your thoughts on the future of optics-free biology.

May 13, 2026 0 comments
0 FacebookTwitterPinterestEmail
Tech

Scientists call for explainable AI in protein language models

by Chief Editor May 12, 2026
written by Chief Editor

Cracking the Protein Code: The Shift Toward Explainable AI in Bio-Engineering

Protein language models (pLMs) are fundamentally changing how we approach biotechnology. These AI tools allow scientists to engineer proteins with useful properties, creating entirely new structures that have never existed in nature. From synthesizing enzymes that can scrub carbon dioxide from the atmosphere to developing industrial catalysts that slash energy consumption and toxic waste, the potential is staggering.

However, a critical hurdle remains: the “black box” problem. While these models can predict a protein’s structure or function with uncanny accuracy, they rarely explain why they reached that conclusion. As pLMs begin to drive real-world biotech decisions, the need for “explainable AI” (XAI) has moved from a luxury to a necessity.

Did you know? Researchers are drawing parallels between protein AI and AlphaZero. Just as AlphaZero uncovered novel chess strategies that surprised grandmasters, a “Teacher” protein model could reveal biological principles of folding and catalysis that humans have never recognized.

Decoding the Decision: Where Does the Explanation Live?

To move beyond the black box, researchers at the Centre for Genomic Regulation (CRG) suggest that we must identify exactly where a model’s predictive decision originates. According to a perspective paper published in Nature Machine Intelligence, there are four critical areas to investigate:

View this post on Instagram about Decoding the Decision, Does the Explanation Live
From Instagram — related to Decoding the Decision, Does the Explanation Live
  • Training Data: Analyzing the data the model learned from can reveal biases, such as a lack of human genetic diversity or insufficient data on specific human proteins.
  • Protein Sequences: Much like a real estate model looks at square footage or location, pLMs look at specific amino acids or regions of a protein to determine which influenced the prediction most.
  • Model Architecture: What we have is the equivalent of “opening the hood” of a car to check the engine, ensuring the artificial neurons are processing information correctly.
  • Input-Output Behavior: By “nudging” the model—slightly altering a protein sequence or the question asked—researchers can observe how the answer changes to understand the model’s logic.

The Evolution of AI Roles: From Evaluator to Teacher

Currently, explainability in protein research is largely used for verification rather than discovery. The researchers have categorized the roles of XAI into a hierarchy of sophistication:

Lecture11 – Protein Language Models – MLCB24

The Current Standard: Evaluators and Multitaskers

Most current studies use XAI as an Evaluator, checking if the AI recognizes patterns biologists already know, such as structural motifs or binding sites. A smaller group uses AI as a Multitasker, reapplying those signals to annotate new proteins or predict additional properties.

The Emerging Frontier: Engineers and Coaches

A limited number of studies are pushing further, using XAI as an Engineer or Coach. In these roles, insights are used to trim unnecessary model components or redesign architectures to steer the AI toward generating sequences with specific, desired traits.

The Holy Grail: The “Teacher” Model

The most ambitious goal is the Teacher model. This would be an AI capable of revealing entirely new biological rules regarding molecular interaction and protein folding. As Dr. Noelia Ferruz, Group Leader at the CRG, explains, the ultimate goal is controllable protein design.

“Imagine being able to tell a model: ‘Design a protein with this shape, active at this pH,’ and not only receive a candidate sequence, but also a clear explanation of why that design should work, and importantly, why alternatives would fail,” says Dr. Ferruz.

Pro Tip: For those implementing pLMs in a lab setting, remember that mathematical patterns are not biological facts. Any AI-derived insight must be validated through laboratory experimentation to turn a prediction into confirmed biological knowledge.

The Road to Trustworthy Bio-Design

Moving toward a “Teacher” status won’t happen by accident. Today’s models are powerful pattern recognizers, but they often rely on statistical correlations rather than a true understanding of biology. To bridge this gap, the research community is calling for three major shifts:

  1. Robust Benchmarks: Creating frameworks to test whether an AI’s explanation actually reflects its internal reasoning.
  2. Open-Source Tooling: Making explainability tools accessible across different labs to ensure results are comparable.
  3. Laboratory Validation: Ensuring that every “insight” provided by the AI is tested in a real-world biological environment.

Without these safeguards, we risk building powerful tools that we cannot fully trust. As Andrea Hunklinger, first author of the CRG paper, notes, “If we want protein language models to become a reliable partner in discovery and design, explainability must not be an afterthought.”

Frequently Asked Questions

What is a Protein Language Model (pLM)?
It is an AI tool that treats protein sequences like a language, allowing researchers to engineer proteins with specific properties or create entirely new structures.

Why is “explainability” important in biotechnology?
Because many AI models act as “black boxes,” it is demanding to know if a prediction is biased, unreliable, or unsafe. Explainable AI (XAI) allows humans to understand and trust the decision-making process.

What would a “Teacher” AI model be able to do?
A Teacher model would go beyond pattern recognition to reveal new biological principles, such as new rules for protein folding or catalysis, effectively teaching scientists something they didn’t previously know.


Join the Conversation: Do you believe AI will eventually replace traditional physics-based models in protein design, or will the “black box” problem always require a human in the loop? Let us know your thoughts in the comments below or subscribe to our newsletter for more insights into the future of medical AI.

May 12, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Scientists map 239 human-infective RNA viruses to track future outbreak risks

by Chief Editor April 27, 2026
written by Chief Editor

The Hidden Map of Viral Threats: Decoding the RNA Landscape

The battle against emerging infectious diseases is often a race against an invisible enemy. A comprehensive new global dataset has recently brought the number of known human-infective RNA virus species to 239. This isn’t just a list; it is a roadmap showing how animal hosts, transmission routes, and surveillance gaps dictate whether a virus remains a rare occurrence or becomes a global crisis.

While the number of recognized species has grown—increasing by 25 since 2018—the data reveals a striking pattern. Most of these viruses are not random anomalies; they cluster within a few specific families and are heavily linked to non-human hosts, particularly mammals.

Did you know? The first human RNA virus ever reported was the Yellow fever virus back in 1901. Since then, discovery rates peaked significantly in the 1960s and again in the early 2000s.

Why Mammals are the Primary Bridge

The data underscores a critical biological reality: mammals are the central players in viral emergence. Most human-infective RNA viruses are associated with non-human mammalian hosts, creating a natural bridge for “spillover” events.

Why Mammals are the Primary Bridge
Level Vector Why Mammals

However, spillover does not automatically lead to a pandemic. The research highlights a critical bottleneck between the initial exposure and sustained human-to-human spread. While many viruses can jump from an animal to a human, only a slight fraction possess the traits necessary to adapt and thrive within human populations.

The Bottleneck: From Spillover to Epidemic Potential

Not all viruses are created equal. Scientists now classify transmissibility into levels to better predict risk. According to the latest findings, 62% of these RNA viruses are strictly zoonotic (Level 2), meaning they can infect a human but cannot spread to another person.

In contrast, only 60 species have reached Level 4, meaning they are either endemic in humans or capable of causing epidemic spread. Even among these high-risk viruses, many still maintain animal reservoirs, making them persistent threats that cannot be easily eradicated.

The Dominance of Vector-Borne Spread

When looking at how these pathogens move, vector-borne transmission—primarily via ticks and mosquitoes—is the dominant route. Here’s followed by inhalation and direct contact pathways.

View this post on Instagram about Vector, The Dominance of Vector
From Instagram — related to Vector, The Dominance of Vector

Recent events involving the Oropouche virus and SARS-CoV-2 serve as stark reminders of how quickly these pathways can lead to widespread outbreaks. The diversity of these routes means that surveillance cannot focus on a single method of transmission if we hope to catch the next threat early.

Pro Tip: To understand the broader context of these threats, explore how metagenomics is used to identify viruses that don’t fit traditional profiles.

Predicting the Next Outbreak: The Future of Surveillance

The future of global health security is shifting from broad, reactive searches to targeted, proactive surveillance. Instead of searching blindly for any new pathogen, experts are now using datasets to pinpoint “high-risk” zones.

Chapter 25 – The RNA Viruses that Infect Humans

Targeting the “Dark Matter” of the Virosphere

The integration of artificial intelligence is revolutionizing discovery. For example, deep learning algorithms like LucaProt are now being used to identify highly divergent RNA viral “dark matter” by integrating sequence and predicted structural information. This allows scientists to find viruses that were previously invisible to standard detection methods.

By focusing on high-risk viral families and mammalian reservoirs in regions where surveillance is currently weak, health organizations can identify undetected spillovers before they evolve into epidemics.

The Role of Real-Time Genomic Sequencing

Closing the knowledge gaps around transmission routes and host ranges requires a commitment to real-time genomic sequencing. When we can map a virus’s genome the moment it emerges, we can determine its “Level” of transmissibility much faster, allowing for more precise public health interventions.

The Role of Real-Time Genomic Sequencing
Level Vector

For more detailed insights on viral classification, you can refer to the full catalogue in Scientific Data.

Frequently Asked Questions

How many RNA viruses are known to infect humans?
As of the complete of 2024, there are 239 recognized species of human-infective RNA viruses.

What is a “zoonotic” virus?
A zoonotic virus is one that is transmitted from animals to humans. Most human RNA viruses (62%) are strictly zoonotic and do not spread from human to human.

Which transmission route is most common for these viruses?
Vector-borne transmission, specifically through mosquitoes and ticks, is the most dominant route of spread.

Why are RNA viruses considered a greater threat than others?
Their ability to rapidly change, their diverse host ranges (especially in mammals), and their potential for epidemic spread—as seen with influenza and SARS-CoV-2—make them a primary focus for public health.

Stay Ahead of the Curve

Do you think AI will eventually allow us to predict a pandemic before the first human case occurs? Share your thoughts in the comments below or subscribe to our newsletter for the latest updates in viral research and global health.

April 27, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Early genomic testing prevents years of inconclusive visits for pediatric patients

by Chief Editor April 21, 2026
written by Chief Editor

The Shift Toward Whole Genome Sequencing as the Gold Standard

The landscape of pediatric genomics is moving rapidly. While trio-based exome sequencing served as the entry-level testing for years, the future of rare disease diagnosis is shifting toward trio whole genome sequencing (WGS). This transition allows clinicians to capture a more complete picture of a patient’s genetic makeup from the start.

The Shift Toward Whole Genome Sequencing as the Gold Standard
Sequencing Disease The Shift Toward Whole Genome Sequencing

By implementing WGS as the primary tool, programs like the Telethon Undiagnosed Disease Program (TUDP) aim to reduce the time families spend in the “diagnostic odyssey”—a period of uncertainty that can often last nearly a decade. This shift is not just about speed; it is about increasing the diagnostic yield for children with severe, complex phenotypes.

Did you know? Systematic reanalysis of unsolved cases has already increased the overall diagnostic yield by more than 17% among previously negative cases, proving that genomic data becomes more informative as scientific knowledge grows.

Integrating Artificial Intelligence for Faster Answers

One of the most significant trends in genomic medicine is the integration of artificial intelligence (AI) tools for variant classification. The sheer volume of data generated by WGS is immense and AI helps scientists sift through thousands of variants to identify the one truly pathogenic mutation.

This technological leap allows for more precise filtering of de novo variants—those that arise spontaneously without prior family history—which account for more than 70% of causative variants in some pediatric cohorts.

Beyond the Exome: Long-Read Sequencing and RNA Analysis

Even with WGS, some genetic mysteries remain. The next frontier involves utilizing more sophisticated tools to detect variants that traditional sequencing misses. This includes whole genome long-read sequencing and optical mapping, which are essential for resolving structurally complex cases.

Beyond the Exome: Long-Read Sequencing and RNA Analysis
Sequencing Disease Therapy

RNA sequencing is becoming a critical tool for detecting deep intronic and splicing variants. By analyzing how genes are expressed rather than just the sequence of the DNA, researchers can pinpoint the exact cause of a disorder that was previously invisible.

Pro Tip: For families navigating rare diseases, utilizing services like gene therapy information hubs or specialized information services can provide vital guidance on referral centers and clinical trials.

Real-World Impact: The Discovery of ReNU Syndrome

The power of continuous reanalysis and advanced genomic strategies is best illustrated by the identification of 11 probands with de novo variants in the RNU4-2 non-coding RNA gene. This discovery led to the recognition of a new neurodevelopmental disorder known as ReNU syndrome.

First Line Genomic Testing: What New AAP Guidance Means for Pediatricians

This case highlights a broader trend: diagnostic programs are no longer just providing answers to families; they are actively discovering new disease-causing genes. The TUDP, for instance, has contributed to the identification of 16 previously unknown genes, with another 14 currently under validation.

From Molecular Diagnosis to Precision Therapy

A molecular diagnosis is no longer the end of the journey; it is the beginning of a personalized treatment plan. The trend is moving toward “precision pharmacology,” where the specific genetic variant dictates the therapy.

We are seeing a rise in targeted interventions, including:

  • Antisense oligonucleotides: Custom-designed molecules to modulate gene expression.
  • Gene Therapy: Directly addressing the genetic root of the condition.
  • Precision Pharmacology: Using the genetic profile to select the most effective medication.

By sharing phenotypic data via global platforms like PhenomeCentral, Decipher, and ClinVar, researchers can match patients worldwide who share the same rare variants, accelerating the development of these life-changing therapies.

FAQ: Understanding Rare Disease Genomics

What is a “diagnostic odyssey”?

It is the prolonged period of uncertainty families face when seeking a diagnosis for a rare disease, often involving repeated specialist visits and inconclusive tests over several years.

FAQ: Understanding Rare Disease Genomics
Sequencing Disease

What is “diagnostic yield”?

Diagnostic yield refers to the percentage of patients in a study or program who receive a definitive genetic diagnosis. For example, the TUDP achieved a yield of 49%.

Why is “trio sequencing” used?

Trio sequencing analyzes the DNA of the affected child and both parents simultaneously. This makes it much easier to identify de novo variants that occurred spontaneously in the child.

Can an “unsolved” case ever be solved?

Yes. Through systematic reanalysis of existing genomic data and the discovery of new disease-genes, cases that were once negative can result in a diagnosis years later.

Join the Conversation

Do you believe AI will eventually eliminate the diagnostic odyssey for all rare diseases? Or do you think the human element of clinical expertise will always be the primary driver? Share your thoughts in the comments below or subscribe to our newsletter for the latest updates in genomic medicine.

April 21, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Study identifies four radiomic profiles linked to sarcoidosis severity

by Chief Editor April 10, 2026
written by Chief Editor

Revolutionizing Sarcoidosis Diagnosis: How AI-Powered CT Scans Are Changing the Game

For the over 150,000 Americans living with sarcoidosis, a complex inflammatory lung disease, diagnosis and monitoring have long been a challenge. Traditional methods rely on visual assessment of chest CT scans, a process prone to variability between specialists. But a recent era in sarcoidosis care is dawning, powered by radiomics – a cutting-edge technology that uses artificial intelligence to unlock hidden insights within these scans.

What is Radiomics and Why Does It Matter?

Radiomics isn’t about replacing radiologists; it’s about augmenting their expertise. This computer-based imaging technique employs advanced algorithms to measure hundreds of quantitative features from medical images, far beyond what the human eye can discern. These features capture subtle patterns in lung tissue, providing a multidimensional characterization of the disease.

View this post on Instagram

“We found that radiomic analysis of CT scans can reveal distinct patterns of lung abnormalities in sarcoidosis,” explains Tasha Fingerlin, PhD, of National Jewish Health. “These patterns were associated with differences in lung function, suggesting that this approach may help us better understand how the disease varies from patient to patient.”

Four Distinct Profiles: Unlocking Sarcoidosis Subtypes

Researchers at National Jewish Health, analyzing CT scans from 320 sarcoidosis patients as part of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) Study, have identified four distinct imaging profiles. These profiles range from patients with minimal lung abnormalities to those exhibiting patterns indicative of significant inflammation or fibrosis. Crucially, these radiomic groups correlated with differences in lung function, even after accounting for traditional imaging assessments.

This discovery is significant because current staging systems, while helpful, don’t always capture the full complexity of the disease. Radiomics offers a more detailed and reproducible way to quantify these patterns.

Beyond Diagnosis: Tracking Disease Progression and Personalizing Treatment

The potential of radiomics extends far beyond initial diagnosis. Because the analysis can be performed quickly and automatically using open-source software, it could enable clinicians to analyze large numbers of scans and track disease patterns over time with unprecedented efficiency.

“Radiomics has the potential to complement the expertise of radiologists by providing objective measurements of lung abnormalities, identifying disease subtypes, monitoring progression and potentially guiding more personalized treatment strategies,” says Dr. Fingerlin.

Lisa Maier, MD, adds that this technology could be particularly impactful in areas lacking specialized sarcoidosis expertise. “There is promise for significant impact on patient care, especially in regions where there is no expert in sarcoidosis radiology… Radiomics could also expedite care in clinics with rapid turnaround for patients at specialized centers and revolutionize the way we interpret CT scans for research and clinical trials.”

The Future of AI in Pulmonary Imaging

The development of radiomic profiling represents a broader trend: the increasing integration of AI into pulmonary imaging. Expect to observe further advancements in this field, including:

  • Predictive Modeling: AI algorithms could predict which patients are most likely to experience disease progression or respond to specific treatments.
  • Automated Reporting: AI-powered tools could generate preliminary reports for radiologists, streamlining the workflow and reducing the risk of errors.
  • Integration with Other Data Sources: Combining radiomic data with genomic information, patient history, and other clinical data could provide a holistic view of the disease.

FAQ

What is sarcoidosis? Sarcoidosis is a complex inflammatory lung disease that affects more than 150,000 people in the United States.

What is radiomics? Radiomics is a computer-based imaging technique that analyzes subtle patterns in medical images using advanced algorithms.

How does radiomics improve sarcoidosis diagnosis? Radiomics provides a more objective and reproducible way to assess lung abnormalities, identifying distinct patterns linked to disease severity and lung function.

Is radiomics widely available? While still an emerging technology, radiomics is becoming increasingly accessible thanks to open-source software and growing research efforts.

Will AI replace radiologists? No, radiomics is designed to augment the expertise of radiologists, not replace them.

Did you know? National Jewish Health is a WASOG (World Association of Sarcoidosis and Granulomatous Disease) Center of Excellence for Sarcoidosis, a designation it has held since 2017.

Pro Tip: Early and accurate diagnosis is crucial for effective sarcoidosis management. Discuss the potential benefits of radiomic analysis with your healthcare provider.

Want to learn more about the latest advancements in lung disease research? Explore our other articles on pulmonary health and innovative diagnostic techniques.

April 10, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

New AI tool assesses the potential threat posed by new bacteria

by Chief Editor March 27, 2026
written by Chief Editor

AI-Powered Pandemic Preparedness: A New Era of Bacterial Threat Detection

Researchers have unveiled a groundbreaking AI tool, PathogenFinder2, poised to revolutionize pandemic preparedness. Developed by a team at the Technical University of Denmark (DTU) and international collaborators, this innovation promises to identify potentially dangerous bacteria before they cause infections, shifting the focus from reactive outbreak control to proactive prevention.

The Challenge of Unknown Threats

The world faces a growing challenge in identifying bacterial threats. Climate change, expanding ecosystems, and increased exploration of microbial diversity are leading to the discovery of more bacterial species than ever before – many of which are undocumented. Traditionally, determining a bacterium’s potential to cause disease has been a slow, costly, and often inconsistent process relying on laboratory experiments. Existing computational methods often falter when faced with entirely new organisms lacking close relatives.

How PathogenFinder2 Works: Decoding the Language of Proteins

PathogenFinder2 takes a fundamentally different approach. Instead of comparing new bacteria to known pathogens, it utilizes protein language models – advanced AI systems trained on millions of protein sequences. These models, similar to text prediction tools, learn the patterns within protein structures, enabling them to detect biochemical signals that traditional methods miss. This allows for the assessment of threats even from completely unknown disease-causing bacteria.

A Bacterial Pathogenic Capacity Landscape

The tool’s capabilities extend beyond simple prediction. By leveraging protein language models, researchers have created the first Bacterial Pathogenic Capacity Landscape, a map illustrating the relationships between thousands of bacteria based on their disease-linked features. This landscape reveals clusters of bacteria that infect similar tissues or share metabolic strategies, offering new insights into microbial evolution and interactions.

Beyond Prediction: Understanding the ‘Why’

PathogenFinder2 doesn’t just flag potentially risky bacteria; it explains why. The tool highlights the specific proteins that contribute most to its assessment, including known virulence factors like toxins and attachment structures, as well as previously uncharacterized proteins that could play a role in disease. This interpretability opens new avenues for research into diagnostics, vaccine development, and understanding infection mechanisms.

Global Collaboration and Accessibility

PathogenFinder2 is a key component of the Global Pathogen Analysis Platform (GPAP) and is freely available as an online service. This accessibility is crucial for fostering international collaboration and ensuring that researchers worldwide can benefit from this technology.

Applications in Diverse Fields

The potential applications of PathogenFinder2 are far-reaching. Researchers can use it to investigate sewage, analyze samples from healthy humans and animals, and identify bacteria with pathogenic potential before the first infection emerges. This proactive approach could significantly accelerate the development of tests, vaccines, and treatments.

The Power of a Massive Dataset

The model’s accuracy is built upon a robust foundation: a dataset of over 21,000 bacterial genomes. This dataset, assembled from international databases, includes bacteria from human infections, the human microbiome, probiotic cultures, food production, and extreme environments. This comprehensive collection allows the model to effectively distinguish between harmful and harmless bacteria, even when encountering previously undescribed species.

FAQ

What is PathogenFinder2?

PathogenFinder2 is an AI tool that predicts the disease-causing potential of bacteria, even those previously unknown.

How does it differ from traditional methods?

Traditional methods rely on comparing bacteria to known pathogens. PathogenFinder2 uses protein language models to analyze bacterial genomes and identify potential threats regardless of similarity to known species.

Is PathogenFinder2 publicly available?

Yes, This proves freely available as part of the Global Pathogen Analysis Platform (GPAP).

What is the Bacterial Pathogenic Capacity Landscape?

It’s a map showing how thousands of bacteria relate to one another based on their disease-linked features, providing insights into microbial evolution and interactions.

Pro Tip: Regularly checking the GPAP for updates and new features can help you stay ahead of emerging bacterial threats.

Explore the potential of PathogenFinder2 and contribute to a more prepared future. Share your thoughts and experiences in the comments below!

March 27, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

CDC tracks SARS-CoV-2 BA.3.2 global rise and finds early signals in U.S. wastewater

by Chief Editor March 26, 2026
written by Chief Editor

Fresh COVID Variant “Cicada” (BA.3.2) Spreads: What You Need to Know

Health officials are closely monitoring a newly emerging COVID-19 variant, BA.3.2, nicknamed “Cicada” due to its prolonged period of undetected circulation. The Centers for Disease Control and Prevention (CDC) recently published a report detailing its spread across the globe and within the United States.

Early Detection Through Advanced Surveillance

The CDC’s report highlights the effectiveness of traveler-based genomic surveillance and wastewater monitoring in detecting BA.3.2 early. The variant was first identified in a respiratory sample from South Africa in November 2024. Since then, it has been reported in 23 countries, with detections increasing since September 2025.

In the U.S., BA.3.2 has been found in nasal swabs from travelers, airplane wastewater, clinical samples from patients, and wastewater samples from 25 states. This multi-pronged approach to surveillance is proving crucial in tracking the virus’s evolution.

Genetic Divergence and Immune Evasion Potential

BA.3.2 is genetically distinct from previous variants, possessing approximately 70-75 substitutions and deletions in the spike protein gene sequence compared to JN.1 and LP.8.1. These changes raise concerns about the variant’s potential to evade immunity from prior infection or vaccination.

The CDC is actively analyzing these mutations to understand their impact on vaccine effectiveness and the severity of illness.

Global Spread and Current Prevalence

Globally, detections of BA.3.2 began to rise in September 2025. By February 11, 2026, the variant had been reported in 23 countries. In some European nations, like Denmark, Germany, and the Netherlands, BA.3.2 accounted for approximately 30% of sequenced cases.

Within the U.S., the prevalence of BA.3.2 among sequenced samples was 0.19% as of February 11, 2026, but has increased to 0.55% by March 12, 2026. The first U.S. Case identified through traveler screening occurred in June 2025, involving a person traveling from the Netherlands.

Sublineages and Ongoing Evolution

Phylogenetic analysis has revealed the emergence of two sublineages, BA.3.2.1 and BA.3.2.2, indicating the virus continues to evolve. Researchers are monitoring these sublineages to assess any changes in transmissibility or immune evasion.

Public Health Response and Future Outlook

While BA.3.2 has demonstrated immune evasion potential, current data does not suggest a more severe illness. All patients identified in the U.S. Have survived. The CDC emphasizes the importance of continued genomic surveillance to track the variant’s spread and inform public health strategies.

Sustained monitoring, combined with studies on vaccine and antiviral effectiveness, will be essential to guide future responses to SARS-CoV-2 variants.

FAQ About BA.3.2

What is the BA.3.2 variant? BA.3.2 is a newly identified SARS-CoV-2 variant with a high number of mutations in the spike protein.

Where was BA.3.2 first detected? It was first detected in South Africa in November 2024.

Is BA.3.2 more dangerous than other variants? Current data does not indicate increased severity, but its immune evasion potential is being closely monitored.

How is the CDC tracking BA.3.2? Through traveler-based genomic surveillance, wastewater monitoring, and national genomic surveillance programs.

Should I be concerned about BA.3.2? It’s key to stay informed and follow public health recommendations, but there is no need for undue alarm at this time.

Did you know? Wastewater surveillance can often detect new variants *before* they are identified in clinical cases, providing an early warning system for public health officials.

Pro Tip: Staying up-to-date with your COVID-19 vaccinations remains the best defense against severe illness, even with the emergence of new variants.

Stay informed about the latest developments in COVID-19 and other public health issues. Read the full CDC report here.

March 26, 2026 0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts

Recent Posts

  • Scott Gregory: From U.S. Open Rock Bottom to Redemption

    June 16, 2026
  • What Is ‘Tanmaxxing’? Why Gen Z Is Skipping Sunscreen

    June 16, 2026
  • US and Iranian Officials to Meet at Bürgenstock for MOU Signing

    June 16, 2026
  • Not Seen in Two Weeks

    June 16, 2026
  • How Emma Heming Is Supporting Bruce Willis Through His Dementia Battle

    June 16, 2026

Popular Posts

  • 1

    Maya Jama flaunts her taut midriff in a white crop top and denim jeans during holiday as she shares New York pub crawl story

    April 5, 2025
  • 2

    Saar-Unternehmen hoffen auf tiefgreifende Reformen

    March 26, 2025
  • 3

    Marta Daddato: vita e racconti tra YouTube e podcast

    April 7, 2025
  • 4

    Unlocking Success: Why the FPÖ Could Outperform Projections and Transform Austria’s Political Landscape

    April 26, 2025
  • 5

    Mecimapro Apologizes for DAY6 Concert Chaos: Understanding the Controversy

    May 6, 2025

Follow Me

Follow Me
  • Cookie Policy
  • CORRECTIONS POLICY
  • PRIVACY POLICY
  • TERMS OF SERVICE

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: o f f i c e @byohosting.com


Back To Top
Newsy Today
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World